

Part B Provider-Administered Precertification Drug List

Effective September 1, 2026

Blue Cross and Blue Shield of Alabama includes the following drugs in the Blue Advantage Part B Provider-Administered Drug Precertification Program. Precertification for these provider-administered drugs is required when administered in a provider's office, outpatient facility, or home health setting. Treatments indicated as Gene Therapy/Cellular Immunotherapy (+) require precertification when administered in any place of treatment.

Abecma+	Carvykti+	Eydenzelt	Jelmyto	Nucala
Abraxane	Casgevy+	Eylea	Jemperli	Nulibry
Actemra IV	Cerezyme	Eylea HD	Jobevne	Nypozi
Adakveo	Cimzia	Fabrazyme	Kadcyla	Nyvepria
Adcetris	Cinqair	Fasenra	Kalbitor	Ocrevus
Adstiladrin+	Cinryze	Faslodex	Kanuma	Ocrevus Zunovo
Aduhelm	Cinvanti	Filkri	Kebilidi	Octagam
Adzynma	Cligavyx	Flebogamma	Keytruda	Omalizumab-igec
Ahzantive	Columvi	Focinvez	Keytruda qlex	Omlyclo
Akynzeo IV	Cortrophin	fosaprepitant	Khapzory	Omvox
Aldurazyme	Cosentyx_IV	Fulvestrant	Kimmtrak	Onpattro
Alimta	Crysvita	Fusilev	Kisunla	Ontruzant
Aloxi	Cutaquig	Fyarro	Kresladi	Opdivo
Alyglo	Cuvitru	Fylnetra	Krystexxa	Opdivo Qvantig
Alymsys	Cyramza	Gamifant	Kymriah+	Opdualag
Amondys 45	Danyelza	Gammagard	Kyprolis	Opuviz
Amtagvi	Darzalex	Gammagard Liquid ERC	Lamzede	Orencia IV
Amvuttra	Darzalex Faspro	Gammagard Liquid ERC SQ	Lemtrada	Otulfii
Andembry	Datroway	Gammaked	Lenmeldy	Oxlumo
Anktiva	Daxxify	Gammplex	Leqembi	Paclitaxel Protein-Bound
Aphexda	Decnupaz	Gamunex-C	Leqvio	Padcev
Aprepitant	Durolane	Gazyva	Leukine	Panzyga
Armupleg	Dysport	Gel-One	Libtayo	Papzimeos
Arzerra	Elahere	Gelsyn-3	Loargys	Pavblu
Asceniv	Elaprase	Genvisc	Loqtorz	Pemfexy
Aucatzyt	Elelyso	Givlaari	Lucentis	Pemtrexed
Avastin*	Elevidys+	Granix	Lumizyme	Pemetrexed Avyxa
Avlayah	Elfabrio	Hemgenix+	Lumoxiti	Penpulimab-kcqx
Avtozma	Elitek	Herceptin	Lumvoa	Perjeta
Avzivi	Elrexio	Herceptin Hylecta	Lunsumio	Phesgo
Bavencio	Elzonris	Hercessi	Lunsumio Velo	Piasky
Belrapzo	Emend	Herzuma	Luxturna+	Polivy
Bendeka	Empliciti	Hizentra	Lyfgenia+	Pombiliti
Benlysta IV	Emrelis	Hyalgan	Lymphir	Portrazza
Beovu	Encelto	Hymovis	Lynozyfic	Poteligeo
Beqvez	Enhertu	Hyqvia	Lytenava	Privigen
Berinert	Enjaymo	Ilaris	Macugen	Procrit
Besponsa	Entyvio	Ilumya	Margenza	Provenge
Bivigam	Enzeevu	Imaavy	Mepsevii	Pyzchiva
Bizengri	Epkinly	Imdelltra	Monjuvi	Qalsody
Bkemv	Epogen	Imfinzi	Monovisc	Qivigy
Blenrep	Epysqli	Imjudo	Mylotarg	Radicava
Blincyto	Erbix	Imlygic	Myobloc	Ranluspec
Bortezomib	Euflexxa	Immogolis Intri	Naglazyme	Reblozyl
Botox	Evdi	Imuldosa	Navitrox	Releuko
Breyanzi+	Evkeeza	Inlexzo (Eff. 3/15/26)	Neupogen	Renflexis
Brineura	Evomela	Itvisma	Nexvazyme	Retacrit
Briumvi	Exdensur	Ixempira	Niktimvo	Revtorpyk
Byooviz	Exondys 51	Izervay	Nplate	Rituxan Hycela

Rituxan IV	Stelara IV	Treanda	Vantas	Xiaflex
Rivfloza	Steqeyma	Tregzi	Vectibix	Xipere
Roctavian+	Stimufend	Trelstar Depot	Vegzelma	Xolair
Rolvedon	Sublocade	Tremfya	Velcade	Yartemlea
Ruconest	Supartz	Triluron	Veopoz	Yervoy
Rybrevant	Sustol	Trivisc	Viltepso	Yesafili
Rybrevant Faspro	Susvimo	Trodelvy	Vimizim	Yescarta+
Ryoncil	Syfovre	Trogarzo	Visco-3	Yesintek
Rystiggo	Sylvant	Truxima	Visudyne	Yimmugo
Rytelo	Synojoynt	Tyenne	Vivimusta	Yondelis
Ryzneuta	Talvey	Tyruko	Vivitrol	Zaltrap
Saphnelo	Tecartus+	Tysabri	Vpriv	Zepzelca
Sarclisa	Tecelra	Tziel	Vyepti	Zevaskyn
Sarclisa Escena	Tecentriq	Udenyca	Vyjuvek+	Ziextenzo
Scenesse	Tecentriq Hybreza	Ultomiris	Vyloy	Ziihera
Selarsdi	Tecvayli	Unloxcyt	Vyondys-53	Zoladex
Simponi Aria	Tepezza	Uplizna	Vyvgart	Zolgensma+
Skyrizi IV	Testopel	Ustekinumab	Vyxeos	Zusduri
Skysona+	Tevimbra	Ustekinumab-aaaz	Vyvgart Hytrulo	Zynlonta
Sodium Hyaluronate	Tezspire	Ustekinumab-aekn	Waskyra	Zynteglo+
Soliris	Tivdak	Ustekinumab-auub IV	Wezlana	Zynyz
Spevigo	Tocilizumab-aazg	Ustekinumab-srlf	Winrevair	
Spinraza	Tocilizumab-anoh	Ustekinumab-stba	Xembify	
Spravato	Tofidence	Ustekinumab-ttwf	Xenpozyme	
Starjemza	Trastuzumab-pkrb	Vabysmo	Xeomin	

Drug Additions

Effective January 1, 2026:

Blenrep
Eydenzelt
Qivigy
Ustekinumab-auub IV
Ustekinumab-srlf

Drug Additions

Effective February 1, 2026:

Cligavyx
Exdensur
Itvisma
Rybrevant Faspro

Drug Additions

Effective March 1, 2026:

Filkri
Lunsumio Velo
Yartemlea

Drug Additions

Effective March 15, 2026:

Inlexzo

Drug Additions

Effective May 1, 2026:

Avlayah
Kresladi
Loargys

Drug Deletion

Effective May 15, 2026:

Dextenza

Drug Additions

Effective July 1, 2026:

Decnupaz
Evdli
Immgolis Intri

Drug Additions

Effective August 1, 2026:

Aprepitant
Lumvoa
Navitrux
Ranluspec

Drug Additions

Effective September 1, 2026:

Armupleg
Lytenava
Revtorpyk
Sarclisa Escena
Tregzi
Waskyra

*Precertification required for oncology uses only.

Product names are the property of their respective owners. This list is updated monthly and is subject to change without notice.

Online policies can be found at [AlabamaBlue.com/Providers/Policies](https://www.alabamablue.com/Providers/Policies).

Blue Advantage® PPO is provided by Blue Cross and Blue Shield of Alabama, an independent licensee of the Blue Cross and Blue Shield Association.